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Abstract: Inosine Acedoben Dimepranol (IAD), licensed for the treatment 
of cell-mediated immune deficiencies associated with viral infections, 
has been reported to impact a variety of immune parameters both in vitro 
and in vivo. Here we report the results from a clinical trial where 
multiple lymphocyte subsets - CD19+ B cells, CD3+ T cells, CD4+ T-helper 
cells, FoxP3hi/CD25hi/CD127lo regulatory T cells (Tregs), CD3-/CD56+ NK 
cells, and CD3+/CD56+ NKT cells - were, together with serum 
immunoglobulins and IgG subclasses, followed during 14 days of IAD 
administration to ten healthy volunteers; these selected from 27 
individuals pre-screened in vitro for their capacity to respond to IAD as 
gauged by increases in the percentage of Treg and / or NKT cells arising 
in PHA-stimulated cultures. While a transient spike and dip in Treg and 
T-helper fractions, respectively, was noted, the outstanding consequence 
of IAD administration (1 g po, qds) was an early and durable rise in NK 
cells. For half the cohort, NK cells increased as a percentage of total 
peripheral blood lymphocytes within 1.5 h of receiving drug. By Day 5, 
all but one of the volunteers displayed higher NK cell percentages, such 
elevation - effectively a doubling or greater - being maintained at 
termination of study. The IAD-induced populations were as replete in 
Granzyme A and Perforin as basal NK cells. The novel finding of IAD 
boosting phenotypically competent NK numbers in healthy individuals 
supports the drug's indicated benefit in conditions associated with viral 
infection and reinforces the potential for uplift where immune 
performance may be compromised. 
 
 
 
 
Highlights 
 
 Inosine Acedoben Dimepranol (IAD) is a licensed immuno-modulatory drug 
 IAD increases the proportion of Treg and NKT cells in vitro 
 A clinical trial was established to assess IAD impact in vivo 
 IAD in vivo promoted a rapid and durable rise in NK cells 
 The trial supports IAD’s indicated benefit in immuno-compromised individuals    
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Abstract 
Inosine Acedoben Dimepranol (IAD), licensed for the treatment of cell-mediated 
immune deficiencies associated with viral infections, has been reported to impact a 
variety of immune parameters both in vitro and in vivo. Here we report the results 
from a clinical trial where multiple lymphocyte subsets – CD19+ B cells, CD3+ T 
cells, CD4+ T-helper cells, FoxP3hi/CD25hi/CD127lo regulatory T cells (Tregs), CD3-
/CD56+ NK cells, and CD3+/CD56+ NKT cells – were, together with serum 
immunoglobulins and IgG subclasses, followed during 14 days of IAD administration 
to ten healthy volunteers; these selected from 27 individuals pre-screened in vitro for 
their capacity to respond to IAD as gauged by increases in the percentage of Treg 
and / or NKT cells arising in PHA-stimulated cultures. While a transient spike and dip 
in Treg and T-helper fractions, respectively, was noted, the outstanding consequence 
of IAD administration (1 g po, qds) was an early and durable rise in NK cells. For half 
the cohort, NK cells increased as a percentage of total peripheral blood lymphocytes 
within 1.5 h of receiving drug. By Day 5, all but one of the volunteers displayed 
higher NK cell percentages, such elevation – effectively a doubling or greater – being 
maintained at termination of study. The IAD-induced populations were as replete in 
Granzyme A and Perforin as basal NK cells. The novel finding of IAD boosting 
phenotypically competent NK numbers in healthy individuals supports the drug’s 
indicated benefit in conditions associated with viral infection and reinforces the 
potential for uplift where immune performance may be compromised.  
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1. Introduction 
Inosine Acedoben Dimepranol (IAD) is a synthetic purine derivative comprising the p-
acetamidobenzoic acid salt of N, N-dimethyl-amino-2-propanol (DiP.PAcBA) and the 
β polymorph of the β anomer of inosine in a 3:1 molar ratio. Also known by its 
tradenames Immunovir, Isoprinosine, Viruxan, Inosiplex, Methisoprinol and Inosine 
Pranobex, IAD, currently registered in 43 countries worldwide, has been licensed 
since 1971 for the treatment of cell-mediated immune deficiencies associated with 
various viral infections including human papillomavirus (HPV), herpes simplex virus 
(HSV), varicella-zoster virus (VZV), cytomegalovirus (CMV), and Epstein-Barr virus 
(EBV) [1]. IAD is also indicated for the treatment of measles virus-induced subacute 
sclerosing panencephalitis (SSPE) and post-viral chronic fatigue syndrome (CFS) [2; 
3].  
Over the four decades since its introduction, numerous in vitro and in vivo studies 
have been undertaken on IAD’s mode of action in both animals and humans. 
Depending on the models used, effects from IAD potentially compatible with its 
clinical indications have been assigned to a range of immune cell subtypes, 
functions, and effectors (e.g. cytokines, antibodies) [4-15]. Amongst these are 
studies demonstrating an ability of IAD to restore otherwise defective NK activity in 
various scenarios of immune compromise, including that associated with: HIV 
infection [16], uremia [17], chronic fatigue syndrome [3], and aging [18].     
The present study was designed to appraise the outcome of IAD administration to a 
cohort of healthy subjects, focusing on several of the major immune players with 
respect to the control of viral infections including, for the first time, an assessment of 
drug action on Treg and NKT subsets. Any modulation of immune parameters 
resulting from administering IAD to the healthy population should likely extend to 
similar outcomes in individuals with those chronic viral conditions for which IAD is 
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 4 
currently indicated. At the same time, studying IAD actions in normal healthy 
volunteers offers a steady (uniform) background on which to gauge any consensual 
change – irrespective of pathogenic state – that may result from its application while 
also having the potential to disclose benefits outside of and additional to current 
indications.    
 
 
2. Materials and Methods 
2.1. Pre-screen of healthy volunteers for competence to respond to IAD in vitro 
Venous blood from 27 healthy individuals was collected into K2 EDTA vacutainers® 
(BD, Oxford, U.K). Peripheral blood mononuclear cells (PBMC) were isolated by 
centrifugation on a layer of Ficoll Paque (GE Healthcare, Chalfont St Giles 
  Buckinghamshire, U.K). Cells were washed in RPMI media supplemented with 
antibiotics (Life technologies, Paisley, U.K) (penicillin 100 U/ml, streptomycin 100 
µg/ml) and resuspended at 1x 106 cells/ml in complete media supplemented with 
10% heat-inactivated FCS (Life Technologies, Paisley,  U.K), L-glutamine (Life 
Technologies, Paisley,  U.K) and antibiotics before stimulation with PHA–L 
(phytohemagglutinin-L; 5 µg/ml (Sigma-Aldrich, Gillingham,   Dorset, U.K)) in either 
the absence or presence of IAD (600 µg/ml) and incubated for 4 days at 37°C and 
5% CO2. The percentage Treg and NKT cells present in the recovered population 
was determined by immunophenotyping as below. 
2.2. Clinical trial  
The ten best responding donors from the pre-screen in vitro were entered into a 
Phase 1 Trial, receiving their first dose of IAD within 21 days of pre-screen. On Days 
1 to 13 of the trial, each of the ten volunteers received a 1 g IAD (po, qds). On the 
morning of Day 14, subjects received a single 1 g oral dose. Samples for serum 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 5 
immunoglobulins and cellular immunophenotyping were taken prior to first dosing 
with IAD on Day 1 and following morning dosing on Days 1, 3, 5, 7, 10, and 14.  
2.3. PBMC isolation and lymphocyte subset phenotyping  
PBMC were isolated from whole blood by centrifugation on a layer of Ficoll Paque 
(GE Healthcare, Chalfont St Giles,   Buckinghamshire, U.K). The plasma layer was 
removed and stored for immunoglobulin assessment (below). Cells were washed in 
RPMI media supplemented with antibiotics (Life Technologies, Paisley, U.K) 
(penicillin 100 U/ml, streptomycin 100 μg/ml) before addition (1x106 cells/well) to a 96 
well plate and washed twice in stain buffer (PBS supplemented with 2% FCS). For 
lymphocyte subset identification, cells were stained with the fluorochrome-conjugated 
antibodies indicated for 30 mins on ice then washed and fixed using BD 
Cytofix/Cytoperm™ Cell Fixation/Permeabilisation kit (according to manufacturers 
instructions) ((BD, Oxford, U.K) and washed again before analysis on a flow 
cytometer. B cells: anti-CD19-PE (BD, Oxford, U.K). T-cells: CD3-V500 (BD, Oxford, 
U.K). T-helper cells: anti-CD3-V500 (BD, Oxford, U.K), anti-CD4-PE/CY7 (Biolegend, 
London, U.K). Tregs: anti-CD4-PE/CY7 (Biolegend, London, U.K), anti-CD127-FITC 
(eBioscience, Hatfield, U.K), anti-CD25-APC (Biolegend, London, U.K), and anti-
CD3-V500 (BD, Oxford, U.K) as above followed by anti-FoxP3-PE (BD, Oxford, U.K) 
for a further 30 mins on ice. CD4+ cells, that were CD25hi, CD127lo and FoxP3+ were 
deemed Tregs. NK and NKT cells: anti-CD3-FITC (BD, Oxford, U.K)  and anti-CD56-
APC (BD, Oxford, U.K). Cells that were CD56+ were deemed NK cells and cells that 
were both CD3+ and CD56+ deemed NKT cells.  
2.4. Granzyme A and Perforin staining 
Frozen PBMC samples from all 10 trial subjects isolated prior to first administration of 
IAD and on day 14 of trial were thawed and stained with anti-CD3-V500 (BD, Oxford 
U.K) and anti-CD56-APC (BD, Oxford U.K) for 30 mins on ice before 
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fixing/permeabilising (as above) and then staining with anti-Granzyme A-PE 
(Biolegend, London, U.K). and anti-Perforin-FITC (Biolegend, London, U.K) for a 
further 30 mins on ice prior to analysis by flow cytometry.   
2.5. Multiparameter Flow Cytometry  
Flow cytometery was performed using a CyAn™ ADP Analyzer (Beckman Coulter 
Ltd, High Wycombe, U.K). Insturument setup and calibration were performed using 
BD  Calibrite Beads™ (BD, Oxford, U.K). Data analysis was done with FlowJo 
software.  
2.6. Assessment of plasma immunoglobulin levels 
Plasma was centrifuged (1000 x g) and the supernatant collected and stored (-80°C) 
until analysis for IgG (IgG SPAplus® kit), IgA (IgA SPAplus® kit), IgM (IgM 
SPAplus® kit),(Binding Site, Birmingham, U.K) and subclasses of IgG (IgG1 (IgG1 
SPAplus kit), 2 (IgG2 SPAplus kit), 3 (IgG3 SPAplus kit), and 4 (IgG4 SPAplus kit) 
(Binding Site, Birmingham, U.K). Methods were followed to manufacturer’s 
instructions. Immunoglobulins were analysed using a Cobas® 6000 analyzer (Roche, 
Burgees Hill, U.K.)  
 
2.7. Statistical Analysis 
Data were tested for normality by the Shapiro-Wilk test. To test whether granzyme or 
perforin levels were different from baseline values, the data were analysed using a 
two-tailed unpaired t test and significance was taken to be p<0.05. For the analysis of 
subset percentages, data were analysed by one way analysis of variance followed by 
a Dunnett’s multiple comparison test comparing levels following treatment to baseline 
levels. Significance was taken to be p<0.05. 
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3. Results 
3.1. In vitro pre-screen of healthy volunteers for competence to respond to IAD 
Table 1. Pre-screen of healthy volunteers by virtue of PBMC response to IAD in vitro 
 
Samplea  Treg NKT Subjectc 
IAD % changeb IAD % change 
1 133 210   
2 27 107   
3 177 66 1 
4 46 122   
6 61 1   
8 95 90 5 
9 31 81   
12 53 -37   
15 48 33   
17 63 3   
18 22 -27   
19 104 -9   
21 45 157   
22 80 0 6 
24 35 2   
25 142 -37 3 
27 65 63 9 
32 65 41 10 
34 53 -40   
36 60 54 8 
37 155 69 2 
38 83 354 7 
40 106 29 4 
42 64 128   
43 81 17   
44 133 33   
45 11 58   
 
a
Blood samples from 27 of 45 volunteers (18 of which were subsequently excluded on basis 
of selection criteria unrelated to data presented herein)
 
b
Percentage change in the Treg or NKT subset (as total of all lymphocytes) due to the 
presence of IAD (600 g/ml) during 4 day stimulation of PBMC with PHA in vitro  
c
Subjects 1-10 selected for inclusion into trial 
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A preliminary study on the capacity of IAD to impact the number and performance of 
specific lymphocyte subsets in vitro disclosed an ability of the drug to increase the 
percentage of Treg and / or NKT cells (including the minority iNKT cell subset as 
defined by reactivity with the monoclonal antibody 6B11) within stimulated cultures of 
PBMC from a majority of the healthy donors investigated: other subsets including 
total T and B cells, CD4+ and CD8+ T cells, and NK cells were neither substantively 
nor reproducibly impacted under these conditions (data not detailed). 
Correspondingly, the degree of change in these parameters on an in vitro pre-screen 
of healthy subjects’ PBMC formed the criterion for volunteer inclusion into a clinical 
trial designed to capture the in vivo influence of IAD on defined lymphocyte subsets, 
together with serum immunoglobulins, over 14 days of continuous administration. 
Table 1 details the influence of IAD (600 g/ml) on the percentage of phenotypically 
defined CD4+ regulatory T cells (Treg) and NK-T cells (CD3+CD56+) arising in 4 day 
cultures of PHA-stimulated PBMC from 27 healthy volunteers. All showed an 
increased percentage of Treg cells in response to IAD with 18 of the 27 also 
increasing the proportion of NKT cells present.   
The universal increase in Treg percentages, noted both in the present and our 
previous pre-clinical studies, established this parameter as the initial guiding factor to 
volunteer selection. An accompanying increase in the percentage of NKT cells 
appearing in culture was chosen as a secondary inclusion factor. Occasional 
samples needed to be discounted and volunteers excluded due to wbc counts laying 
outside of the normal range while others failed to progress due to self-withdrawal of 
volunteers from continuation to trial. Of the ten remaining best responding volunteers 
based on Treg increases all but one had an accompanying increase in NKT cells and 
these ten were selected to enter into the Phase I Trial, receiving their first dose of 
IAD within 21 days of pre-screen. 
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3.2. Consequence of IAD administration on serum immunoglobulins 
Figure 1. Influence of IAD administration on plasma immunoglobulins in healthy volunteers 
 
 
 
 
 
 
 
 
 
Plasma immunoglobulins of ten subjects (S1-10) receiving a 1 g oral dose of IAD 4 times 
daily (with a single 1 g oral dose on the morning of Day 14) were assessed prior to first 
dosing Day 1 and following morning dosing on Days 1, 3, 5, 7, 10, and 14: (a) IgG; (b); IgM; 
(c) IgA. 
On Days 1 to 13 of the trial, each of the ten volunteers received a 1 g oral dose of 
IAD 4 times daily. On the morning of Day 14, subjects received a single 1 g oral 
dose. Samples for serum immunoglobulins and immunophenotyping were taken prior 
to first dosing with IAD on Day 1 and following morning dosing on Days 1, 3, 5, 7, 10, 
and 14.  
Over the 14 days of the trial, serum levels of the three major immunoglobulins – IgG, 
IgA, and IgM – essentially remained constant across the subjects (Fig.1). Pre-dosing 
and Day 14 serum samples were additionally measured for the four IgG isotypes, 
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again showing IAD without impact on either IgG1, IgG2, IgG3, or IgG4 
concentrations (Fig.2).   
Figure 2. Plasma IgG subclasses before and after IAD administration 
 
 
 
 
 
 
 
 
 
From the 10 subjects (S1-10) entered into the clinical trial, stored plasma was thawed from 
the Day 1 pre-drug administration and Day 14 post-administration time points and IgG isotype 
levels measured by subclass-specific ELISA: (a) IgG1; (b) IgG2; (c) IgG3; (d) IgG4. 
3.3. Consequence of IAD administration on peripheral lymphocyte subsets  
As can be seen from Fig. 3a-b, no substantive, durable pattern of change over 
baseline was observed during the 14 days of drug adminstration in either overall B- 
or T-cell compartments; neither in the CD4+ T-helper subset, apart from a brief dip at 
Day 5 (Fig. 3c). The same held true for phenotypically-defined Treg cells: with the 
exception of a transient spike at Day 3 (Fig. 3d).  
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Figure 3. Influence of IAD administration on lymphocyte subset distribution in healthy 
volunteers  
Lymphocyte subset distribution among PBMC of ten subjects (S1-10) receiving IAD (as for 
Fig.1) was assessed prior to first dosing Day 1 and following morning dosing on Days 1, 3, 5, 
7, 10, and 14: (a) CD19+ B cells; (b) CD3+ T cells; (c) CD4+ T-helper cells; (d) 
FoxP3+CD25
hi
CD127
lo
 Treg cells (as %CD4+ T cells); (e) CD3-CD56+ NK cells; (f) 
CD3+CD56+ NK cells. 
The consistent, and by far the most compelling change, was an increase in the 
percentage of NK cells among the total lymphocyte population (Fig. 3e). The 
increase commenced early among the cohort: the majority between 1 - 3 days of IAD 
administration; with five subjects evidencing augmented NK cell percentages 1.5 h 
after first dosing. By Day 5, all but one volunteer had a higher proportion (over 
baseline) of their lymphocytes represented by NK cells: this effectively greater than 
doubling of the NK contribution being maintained at Day 14 (trial termination).  
Among the rarer NKT subset, there was a suggestion of change – primarily an 
increase. However, no clear or consistent pattern reaching statistical significance 
was discerned across the ten subjects (Fig. 3f).  
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Statistically significant increased NK cell percentages arising from IAD administration 
as judged by mean change across the ten subjects were registered at Day 5 (mean 
fold increase = 2.1, p<0.05), Day 10 (2.6, p<0.01), and Day 14 (2.1, p<0.05). With 
the exceptions of Treg cells on Day 3 (mean fold increase = 1.8, p<0.05) and T-
helper cells on day 5 (mean fold decrease = 0.6, p<0.01) no other signifcant change 
in any of the subsets as a result of administering IAD was observed. 
Figure 4. Influence of IAD administration on NK cells subsets in healthy volunteers 
 
As for Fig. 3 but with CD3-CD56+ NK cells gated by virtue of CD56
dim
 vs. CD56
bright
 
expression and mean values +/- SEM from the ten subjects plotted (one-way ANOVA 
followed by Dunnett’s multiple comparison test). * p<0.05 compared to Day 1 pre-admin; ** 
p<0.01 compared to Day 1 pre-admin 
Next, the NK population was interrogated with respect to CD56bright versus CD56dim 
subsets: the former being abundant cytokine producers but only weakly cytotoxic 
before activation [19]. As expected, the CD56bright susbset was the minor of the two 
populations in each of the subjects and throughout the course of the trial. Changes in 
the majority CD56dim subset mirrored those seen in the total NK population as might 
be anticipated (Fig. 4). Overall, the minority CD56bright subset showed less of a trend 
towards increasing in frequency than the the CD56dim subset. Only at Day 10 was 
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there a siginficantly (p<0.05) increased percentage of CD56bright NK cells compared 
to pre-administration of IAD.  
3.4. IAD-augmented NK cells contain Granzyme A and Perforin 
Figure 5. Percentage of NK cells positive for Granzyme A and Perforin before and after IAD 
administration 
 
 
 
 
 
 
 
 
From the 10 subjects (S1-10) entered into the clinical trial, stored cells were revived from the 
Day 1 pre-drug administration and Day 14 post-administration time points. Each population 
was assessed for the percentage of CD3-CD56+ cells expressing Granzyme A (upper panel) 
or Perforin (lower panel), respectively. 
The CD3-/CD56+ NK cell population was then assessed for the presence of two key 
NK effector molecules: Granzyme A and Perforin. Unlike above where cells were 
studied direct from volunteers, the measure of Granzyme A and Perforin was made 
retrospectively on previously frozen PBMC from the participants of the clinical trial. 
Notably, the augmented contribution from CD3-/CD56+ cells to total PBMC as a 
consequence of IAD administration was as evident in frozen as in fresh cells. Again, 
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all but one of the ten subjects demonstrated such an increase which at Day 14 
averaged (over all subjects) 1.7-fold (p<0.05) compared to baseline. 
Figure 5 shows that among CD3-CD56+ cells, the percentage positive for Granzyme 
A or Perforin remained as high in the Day 14 IAD-impacted population as was 
observed pre-drug administration on Day 1.  
 
4. Discussion 
The impact of IAD on NK cells registered in the present study is compatible with and 
supports its current indication for the management of viral infections and associated 
complications. A beneficial influence on NK cells was shown to begin early, rise 
progressively, and persist throughout the 14 days of IAD administration to the 
participants of the clinical trial. Remarkably, all subjects showing this IAD-promoted 
NK uplift were healthy, without sign or manifestation of immune compromise. IAD 
has been used widely and studied intensely for four decades with no evidence of it 
promoting lymphopenia. The observed increase in percentage NK cells amongst total 
lymphocytes therefore likely results from a boost in absolute cell number. Indeed, on 
enumerating subsets within the PBMC fraction collected from Ficoll gradients during 
the trial, the NK population at Day 14, for example, now averaged 225% greater in 
number than at baseline (i.e. Day 1 pre-drug administration). While caveats must be 
placed around the accuracy of extrapolating these numbers directly to whole blood 
counts, such pattern of increased recovered NK cells was consistent over time while 
no other subset registered such magnitude of change by this measure.  
Evidence for IAD impacting NK cells has been reported previously though never 
before documented as early and consistently, nor among healthy subjects, as here. 
Many of the historical studies focused on IAD restoring NK cell activity and / or 
number in individuals that were otherwise deficient in this aspect. For example, Diaz-
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Motoma and colleagues [3] described how among CFS patients administered IAD 
over 12 weeks, those showing clinical improvement to drug correspondingly 
manifested increased NK number and function where before both were suppressed. 
Bekesi et al [16] reported how 28 days of IAD administration ‘normalized’ otherwise 
depressed NK cell number and function in homosexual males at high risk of AIDS. 
The same group had earlier reported that both halfway through and a year on from a 
28 day administration regime, immunodepressed patients with prolonged generalized 
lymphadenopathy showed improved NK activity [20]. A rare previous study on 
healthy individuals reported IAD administration augmenting NK activity among 
peripheral blood cells following drug cessation but did not interrogate NK numbers 
[21]. With respect to in vitro action, IAD has been reported as restoring otherwise 
depressed NK activity in the elderly [18] and in patients with uremia [17] with one 
study observing a boost in NK activity from the peripheral blood of healthy subjects 
[22].  
The steady longitudinal in vivo action of IAD on NK cells was not matched across 
other immune parameters investigated. This was despite the clinical trial being 
predicated on a pre-clinical study that disclosed an unexpected property of IAD: its 
ability to increase the proportion of Treg and NKT cells contained within PBMC 
populations. Indeed, efficacy in this regard provided the basis of the pre-screen of 
volunteers for recruitment into the trial here. Notwithstanding, within the trial there 
was a suggestion / trend of IAD positively modulating NKT percentages and while 
there was no overt durable increase in the Treg fraction, a statistically significant 
doubling of Tregs as a consequence of IAD administration was observed at Day 3.  
It should be noted that in the pre-clinical study, the action of IAD was followed 
against PBMC undergoing stimulation (PHA): here, individual subsets have the 
potential to expand and / or die selectively. The immune status of the healthy 
subjects within the trial would instead be ‘resting’, basal. These differences could, 
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potentially, account for the greater impact of IAD on Treg and NKT fractions in vitro 
as compared to what was observed in vivo. Conversely, the clear NK increase 
observed during the trial was not predicted from the prior in vitro study of IAD impact 
on PHA-stimulated PBMC (nor indeed against unstimulated PBMC; Gardiner et al, 
School of Biochemistry & Immunology, TCD, unpublished observations). This being 
the case, then a conceivable mechanism behind the observed NK increase in vivo – 
underscored by it starting early – is one of IAD promoting mobilization of cells from 
tissue reservoirs to blood. While NK cells are actively recruited from blood to sites of 
viral infection [23], in order to accumulate in effective numbers in the target organ, 
NK cells must first of all mobilize from spleen and bone marrow stores to peripheral 
blood [24]. Thus agents – seemingly like IAD here – that facilitate the latter would be 
considered beneficial in such a scenario. Within this context, it is of note that the 
minority CD56bright NK subset showed a less impressive increase during the trial than 
the majority CD56dim population. Though the CD56bright subset appears to dominate in 
selected body tissues, the opposite holds true for spleen and bone marrow where 
CD56dim NK cells prevail [25]. 
The present study confirms and extends the rationale for IAD being considered as a 
useful medicament for disease modification in the context of viral infections. 
Moreover, the lack of any major impact on overall B- or T-cell number, or on serum 
immunoglobulins underscores the drug’s established safety profile. That the IAD-
induced blood NK cells were replete in Granzyme A and Perforin supports earlier 
clinical studies describing augmented NK activity among isolated PBMC following 
IAD administration [3; 21; 26]. While the limitation on blood sample size (and 
correspondingly cell numbers available) during the present Phase I trial precluded 
the ability to assess NK cytotoxicity directly, the earlier studies demonstrating IAD 
augmenting NK function [3; 21; 26] together with the observed increase here in the 
percentage of cells carrying the two cytotoxic effectors are each compatible with IAD 
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increasing functionally competent NK cells in healthy individuals. Moreover, a 
separate in vitro study revealed IAD increasing the percentage of Granzyme B (GrB)-
positive NK cells in donors deplete in basal GrB (Gardiner et al, School of 
Biochemistry & Immunology, TCD, unpublished observations). The NK axis has a 
vital role in several key aspects of host defence and immune surveillance: its 
importance in combating and protecting from multiple classes of virus is undisputed. 
As an example, a recent review details the central contribution of NK cells to the 
control of: influenza virus, CMV, HIV-1, and hepatitis C virus [27]. With regards to 
influenza, it has been suggested that NK lymphopenia may correlate with increased 
disease severity [28]. Of note, in this context, is a recent independent Phase 4 trial in 
a large patient cohort with confirmed acute respiratory viral infections where IAD was 
deemed not only safe but also effective in non-obese subjects less than 50 years of 
age with clinically diagnosed influenza-like illnesses in terms of time to resolution of 
associated disease symptoms [29].  
Through a capacity to enrich blood in phenotypically adept NK cells – as shown here 
– IAD gains the potential to offer benefit against viral infection in a variety of settings 
including otherwise healthy individuals and perhaps, importantly, our growing elderly 
population where NK performance is known to be compromised and where its 
underperformance may be a key contributor to the increased rates of viral infection 
associated with immunesenescence [18; 30; 31].  
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